Scarica l'app Stockscreener
3.9601
1.00%
-0.0399
Pre-mercato:
3.96
-0.0001
-0.00%
Intensity Therapeutics Inc Borsa (INTS) Ultime notizie
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Intensity Therapeutics (INTS) Q2 2026 Earnings Call Transcript - aol.com
Intensity Therapeutics, Inc. Q2 2026 Earnings Call Summary - finance.yahoo.com
Intensity Therapeutics Warns of Substantial Doubt - Minichart
Intensity Therapeutics Q2 Results: EPS loss narrows 67% YoY - scanx.trade
INTS: Q2 2026 saw higher R&D spend, resumed trial enrollment, and strong early TNBC efficacy data - TradingView
Transcript : Intensity Therapeutics, Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Form 8K Intensity Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
INTS: Net loss rose 19% to $3M as clinical trials resumed, with $9.5M cash and $30M more needed for completion - TradingView
Earnings call transcript: Intensity Therapeutics misses Q2 2026 EPS as shares slip premarket - Investing.com
Intensity Therapeutics (INTS) Advances Clinical Trials Amidst Ch - GuruFocus
Intensity Therapeutics Reports $3.0 Million Q2 Net Loss - Quiver Quantitative
Intensity Therapeutics reports Q2 2026 net loss of $3.0M, cash $9.5M; resumes select trial enrollment - TradingView
Intensity Therapeutics Q2 net loss widens as R&D costs rise - TradingView
INTS: Resumed clinical trial enrollment and raised capital, with improved early TNBC study results - TradingView
BRIEF-Intensity Therapeutics Q2 Operating Income USD -3.084 Million - TradingView
Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
INTENSITY THERAPEUTICS, INC. Q2 2026: Net income $(3.0M), EPS $(1.11) — 10-Q Summary - TradingView
INTS Q2'26 Earnings: EPS estimate is (0.87) USD - TradingView
BRIEF-Intensity Therapeutics Q1 Operating Income USD -2.526 Million - TradingView
Intensity Therapeutics (INTS.US) will release its earnings report on August 11. - Moomoo
Intensity Therapeutics Inc (INTS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Intensity Therapeutics Inc (INTS) Stock News Today - TradingKey
Intensity Therapeutics (INTS.US) will release its earnings report before the market opens on August 11. - Moomoo
Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 - Yahoo Finance
INTS Q2'26 Earnings: revenue estimate is 0 USD - TradingView
INTS|Intensity Therapeutics Inc|Price:4.570|Chg%:+0.120 - TradingKey
INTS|Intensity Therapeutics Inc|Price:3.960|Chg%:-0.040 - TradingKey
Intensity Therapeutics Inc (INTS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Intensity Therapeutics Inc (INTS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Intensity Therapeutics Inc (INTS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Intensity Therapeutics Inc (INTS) Balance Sheet - TradingKey
Intensity Therapeutics Inc (INTS) Income Statement - TradingKey
Intensity Therapeutics Inc (INTS) Cash Flow - TradingKey
INTS|Intensity Therapeutics Inc|Price:4.450|Chg%:+0.030 - TradingKey
INTS Stock Price, Quote & Chart - ChartMill
Intensity Therapeutics (INTS) Proxy filing Summary - Quartr
Intensity Therapeutics (INTS) Q1 2026 earnings summary - Quartr
Director Mark Goldberg awarded 5,500 options at Intensity Therapeutics (INTS) - Stock Titan
Intensity Therapeutics (INTS) awards director 5,500 options at $4.90 strike - Stock Titan
Intensity Therapeutics grants 5,500-share option to director | INTS Insider Trading - Stock Titan
Intensity Therapeutics (INTS) director awarded 5,500 stock options at $4.90 - Stock Titan
Intensity Therapeutics (INTS) grants 11,000 stock options to accounting officer - Stock Titan
Intensity Therapeutics (INTS) awards CFO 34,000 stock options at $4.90 - Stock Titan
Intensity Therapeutics grants 78,000 options to CEO | INTS Insider Trading - Stock Titan
Intensity Therapeutics Restarts Phase 2 TNBC Trial - t.co
Intensity Therapeutics (INTS) Edges Higher, Holding Above Key Support at $4.66Fear Greed Extreme - dars.gov.et
New patients dosed with INT230-6 in Swiss trial for aggressive triple-negative breast cancer - Pluang
Intensity Therapeutics (INTS) AGM 2026 Summary - Quartr
Intensity Therapeutics (INTS) Q4 2025 earnings summary - Quartr
Intensity Therapeutics restarts 61-patient breast cancer trial - grafa.com
Intensity Therapeutics resumes patient dosing in Swiss trial - Investing.com
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - The AI Journal
Intensity Therapeutics resumes patient dosing in Swiss trial By Investing.com - Investing.com Canada
Intensity Therapeutics (INTS) Surges 6.6%: Testing Key Resistance After Strong SessionInverse ETF Flow - dars.gov.et
0.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):